Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia - Full Text View

Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia (SMARTER)

This study is currently recruiting participants.

Verified by AstraZeneca, December 2007

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00576316

Purpose

The purpose of the study is to evaluate the satisfaction level of patients using the Symbicort SMART approach for their asthma management.

Condition	Intervention	Phase
Asthma	Drug: Symbicort Turbuhaler 160/4.5	Phase IV

MedlinePlus related topics: Asthma

Drug Information available for: Symbicort

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study
Official Title:	Symbicort Maintenance And Reliever Therapy - Experience in Real Life Setting in Malaysia - SMARTER Study

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

To evaluate the satisfaction level from a patient's perspective using the Symbicort SMART approach by evaluating the changes in Satisfaction of Asthma Treatment Questionnaire (SATQ) scores after 6 months.

Secondary Outcome Measures:

The evaluate the clinical efficacy of Symbicort SMART approach by evaluating changes in ACQ scores after 6 months of treatment.

Estimated Enrollment:	200
Study Start Date:	December 2007

Eligibility

Criteria

Inclusion Criteria:

Diagnosis of asthma for past 6 months and treated with inhaled glucocorticosteroids for at least 3 months.
Patients who asthma is classified as uncontrolled or partially controlled as defined by GINA 2006 guidelines.

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00576316

Contacts

Contact: AstraZeneca Sdn Bhd Malaysia Clinical Study, Information

+603 20892288

Locations

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:	Akhmal Yusof, MD	AstraZeneca
Principal Investigator:	Aziah Ahmad Mahayiddin, MD	Kuala Lumpur Hospital

More Information

Study ID Numbers:	D5890L00027
Study First Received:	December 17, 2007
Last Updated:	February 4, 2008
ClinicalTrials.gov Identifier:	NCT00576316
Health Authority:	Malaysia: Ministry of Health

Keywords provided by AstraZeneca:

Asthma

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Symbicort
Respiratory Tract Diseases

Lung Diseases
Hypersensitivity, Immediate
Asthma
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Respiratory System Agents
Immune System Diseases
Bronchial Diseases

Therapeutic Uses
Anti-Asthmatic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009